Skip to Content

News Release

RxSight, Inc. to Report First Quarter 2022 Financial Results on May 5, 2022 

Apr 21, 2022

ALISO VIEJO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – April 21, 2022 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the first quarter 2022 after the market close on Thursday, May 5, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at, on the Investors page in the News and Events section. The call will also be available by dialing 877-545-0523 (U.S.) or 973-528-0016 (International) five to ten minutes prior to the start time, using conference ID: 217735.

About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight can be found at

Investor Relations Contact:
Philip Taylor
Gilmartin Group

Company Contact:
Shelley Thunen
Chief Financial Officer